Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK)
HKD 0.14
(1.41%)
HKD 0.14
(1.41%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.06 Billion CNY | 7.92% |
| 2022 | 986.69 Million CNY | 17.63% |
| 2021 | 838.8 Million CNY | -18.67% |
| 2020 | 1.03 Billion CNY | -4.58% |
| 2019 | 1.08 Billion CNY | 24.65% |
| 2018 | 867.12 Million CNY | 9.72% |
| 2017 | 790.28 Million CNY | 4.11% |
| 2016 | 759.11 Million CNY | 5.24% |
| 2015 | 721.34 Million CNY | 11.27% |
| 2014 | 648.26 Million CNY | 5.98% |
| 2013 | 611.66 Million CNY | 15.31% |
| 2012 | 530.45 Million CNY | 11.76% |
| 2011 | 474.65 Million CNY | 1140.73% |
| 2010 | 38.25 Million CNY | 935.06% |
| 2009 | 3.69 Million CNY | -77.34% |
| 2008 | 16.31 Million CNY | 0.93% |
| 2007 | 16.16 Million CNY | -19.92% |
| 2006 | 20.18 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 280.32 Million CNY | 15.99% |
| 2024 Q2 | 264.17 Million CNY | -5.76% |
| 2023 Q2 | 255.81 Million CNY | -14.65% |
| 2023 FY | 1.06 Billion CNY | 7.92% |
| 2023 Q3 | 267.64 Million CNY | 4.63% |
| 2023 Q1 | 299.71 Million CNY | 0.82% |
| 2023 Q4 | 241.68 Million CNY | -9.7% |
| 2022 FY | 986.69 Million CNY | 17.63% |
| 2022 Q4 | 297.29 Million CNY | 18.67% |
| 2022 Q1 | 215.69 Million CNY | -10.88% |
| 2022 Q2 | 223.17 Million CNY | 3.46% |
| 2022 Q3 | 250.53 Million CNY | 12.26% |
| 2021 Q1 | 219.28 Million CNY | -19.28% |
| 2021 Q4 | 242.02 Million CNY | 17.73% |
| 2021 Q3 | 205.58 Million CNY | 19.59% |
| 2021 FY | 838.8 Million CNY | -18.67% |
| 2021 Q2 | 171.9 Million CNY | -21.61% |
| 2020 Q4 | 271.68 Million CNY | -9.48% |
| 2020 FY | 1.03 Billion CNY | -4.58% |
| 2020 Q1 | 194.84 Million CNY | -38.53% |
| 2020 Q2 | 264.69 Million CNY | 35.85% |
| 2020 Q3 | 300.14 Million CNY | 13.39% |
| 2019 Q3 | 288.17 Million CNY | 11.34% |
| 2019 Q2 | 258.83 Million CNY | 19.34% |
| 2019 FY | 1.08 Billion CNY | 24.65% |
| 2019 Q1 | 216.88 Million CNY | -10.29% |
| 2019 Q4 | 316.97 Million CNY | 9.99% |
| 2018 Q1 | 205.74 Million CNY | -13.05% |
| 2018 FY | 867.12 Million CNY | 9.72% |
| 2018 Q4 | 241.76 Million CNY | 10.02% |
| 2018 Q3 | 219.74 Million CNY | 9.36% |
| 2018 Q2 | 200.94 Million CNY | -2.33% |
| 2017 FY | 790.28 Million CNY | 4.11% |
| 2017 Q3 | 205.87 Million CNY | 9.49% |
| 2017 Q2 | 188.03 Million CNY | 17.7% |
| 2017 Q1 | 159.75 Million CNY | -35.85% |
| 2017 Q4 | 236.62 Million CNY | 14.93% |
| 2016 Q1 | 142.21 Million CNY | -37.52% |
| 2016 Q2 | 192.19 Million CNY | 35.14% |
| 2016 Q3 | 175.68 Million CNY | -8.59% |
| 2016 FY | 759.11 Million CNY | 5.24% |
| 2016 Q4 | 249.02 Million CNY | 41.74% |
| 2015 Q1 | 150.87 Million CNY | -11.21% |
| 2015 Q2 | 178.97 Million CNY | 18.62% |
| 2015 FY | 721.34 Million CNY | 11.27% |
| 2015 Q4 | 227.62 Million CNY | 38.9% |
| 2015 Q3 | 163.87 Million CNY | -8.43% |
| 2014 FY | 648.26 Million CNY | 5.98% |
| 2014 Q2 | 167.2 Million CNY | 12.17% |
| 2014 Q4 | 169.92 Million CNY | 4.84% |
| 2014 Q3 | 162.07 Million CNY | -3.07% |
| 2014 Q1 | 149.06 Million CNY | -3.69% |
| 2013 FY | 611.66 Million CNY | 15.31% |
| 2013 Q4 | 154.77 Million CNY | -2.67% |
| 2013 Q1 | 157.92 Million CNY | 26.4% |
| 2013 Q3 | 159.02 Million CNY | 13.64% |
| 2013 Q2 | 139.93 Million CNY | -11.39% |
| 2012 Q2 | 140.71 Million CNY | 6.47% |
| 2012 Q4 | 124.93 Million CNY | -5.82% |
| 2012 Q3 | 132.65 Million CNY | -5.73% |
| 2012 Q1 | 132.15 Million CNY | 19.78% |
| 2012 FY | 530.45 Million CNY | 11.76% |
| 2011 Q3 | 123.6 Million CNY | 10.48% |
| 2011 FY | 474.65 Million CNY | 1140.73% |
| 2011 Q1 | 128.83 Million CNY | 249.45% |
| 2011 Q2 | 111.87 Million CNY | -13.16% |
| 2011 Q4 | 110.33 Million CNY | -10.74% |
| 2010 Q1 | 763 Thousand CNY | 107.9% |
| 2010 FY | 38.25 Million CNY | 935.06% |
| 2010 Q4 | 36.86 Million CNY | 12189.33% |
| 2010 Q3 | 300 Thousand CNY | -7.69% |
| 2010 Q2 | 325 Thousand CNY | -57.4% |
| 2009 Q2 | 38 Thousand CNY | 0.0% |
| 2009 Q3 | 524 Thousand CNY | 1278.95% |
| 2009 FY | 3.69 Million CNY | -77.34% |
| 2009 Q4 | 367 Thousand CNY | -29.96% |
| 2008 FY | 16.31 Million CNY | 0.93% |
| 2007 FY | 16.16 Million CNY | -19.92% |
| 2006 FY | 20.18 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | -310.893% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | 89.887% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -1701.856% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | -35.845% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | -10.774% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | -1.123% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | 37.602% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | -31.609% |
| PuraPharm Corporation Limited | 406.85 Million HKD | -161.727% |
| SSY Group Limited | 6.46 Billion HKD | 83.524% |
| JBM (Healthcare) Limited | 648.41 Million HKD | -64.225% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | 27.452% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 99.606% |